0

- VITT is linked to adenovirus-based COVID-19 vaccines. - The immune response targets platelet factor 4 (PF4). - Key immune trigger identified: adenoviral core protein VII (pVII). - Advanced techniques like mass spectrometry utilized in research. - Shared genetic mutation (K31E) found in anti-PF4 antibodies. - Future vaccines can be designed to avoid this reaction. - Researchers highlight need for further studies on vaccine safety. - Findings may influence future adenoviral vaccine design.